Alembic Pharmaceuticals Ltd. NSE: APLLTD | BSE: 533573

Slowing Down Stock

In 5 Starfolio Baskets

Download real time

843.40 6.75 (0.81%)

13,474

NSE+BSE Volume

NSE 31 Dec, 2025 12:06 PM (IST)

Alembic Pharma News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Alembic Pharma from all sources in a single place.

Alembic Pharmaceuticals Ltd.

26 Dec 2025

843.40

0.81%

SAST

Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window

BSE India

Intimation of Closure of Trading Window.

Alembic Pharmaceuticals Ltd.

25 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith Newspaper Publication related to notice of Loss of Share Certificate.

Alembic Pharmaceuticals Ltd.

18 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited announces USFDA approval for Travoprost Ophthalmic Solutions

Alembic Pharmaceuticals Ltd.

16 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

Please find attached herewith announcement under Regulation 30 of SEBI (LODR) Regulations, 2015

Alembic Pharmaceuticals Ltd.

15 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached Newspaper Publication of Special Window for re-lodgement of transfer of physical shares.

Alembic Pharmaceuticals Ltd.

12 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith a copy of advertisement elated to notice of loss of equity share certificate published by Company.

Alembic Pharmaceuticals Ltd.

11 Dec 2025

843.40

0.81%

Alembic gets USFDA nod for generic eye infection treatment suspension

Business Standard

Alembic Pharmaceuticals Ltd on Thursday said it has received final approval from the US health regulator for its generic version of Loteprednol Etabonate and Tobramycin ophthalmic suspension used for treatment of eye infection. The approval granted by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension of strength 0.5 per cent/0.3 per cent (5 mL and 10 mL), Alembic Pharmaceuticals Ltd said in a regulatory filing. Alembic was granted a Competitive Generic Therapy (CGT) designation for this application. With this approval, Alembic is eligible for 180 days of CGT exclusivity upon commercialisation, it added. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5 per cent/0.3 per cent, of Bausch & Lomb Incorporated, the company said. Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5 per cent/0.3 per cent, is...

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals gets USFDA nod for generic eye infection treatment suspension

Business Line | 11 Dec 2025

Alembic Pharmaceuticals Ltd.

11 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited receives USFDA Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%

Alembic Pharmaceuticals Ltd.

09 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith a copy of advertisement related to notice of loss of equity share certificate.

Alembic Pharmaceuticals Ltd.

04 Dec 2025

843.40

0.81%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

One on One meeting with ICICI Prudential Pharma Fund

Is Alembic Pharmaceuticals Ltd. worth buying?

241 Votes:

Buy 83.82%

Sell 8.3%

Hold 7.88%

RESEARCH REPORTS

Buy SEE REPORTS >

Hold SEE REPORTS >